PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

NCT03013491 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

196

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Solid Tumor
Lymphoma

Interventions

DRUG: CX-072
DRUG: ipilimumab
DRUG: vemurafenib

Sponsor

CytomX Therapeutics